| 1 |
Kuznetsova AI, Munchak IM, Lebedev AV, Tumanov AS, Kim KV, Antonova AA, Ozhmegova EN, Pronin AY, Drobyshevskaya EV, Kazennova EV, Bobkova MR. Genetic diversity of capsid protein (p24) in human immunodeficiency virus type-1 (HIV-1) variants circulating in the Russian Federation. Problems of Virology 2023;68:66-78. [DOI: 10.36233/0507-4088-161] [Reference Citation Analysis]
|
| 2 |
Liu Z, Julius P, Kang G, West JT, Wood C. Subtype C HIV-1 reservoirs throughout the body in ART-suppressed individuals. JCI Insight 2022;7. [PMID: 36278485 DOI: 10.1172/jci.insight.162604] [Reference Citation Analysis]
|
| 3 |
de Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, Devel L, Dufour A. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol Rev 2022;74:712-68. [PMID: 35738680 DOI: 10.1124/pharmrev.121.000349] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 4 |
Cafaro A, Ensoli B. HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine. Expert Rev Vaccines 2022;:1-11. [PMID: 35695268 DOI: 10.1080/14760584.2022.2089119] [Reference Citation Analysis]
|
| 5 |
Kuznetsova AI, Gromov KB, Kireev DE, Shlykova AV, Lopatukhin AE, Kazennova EV, Lebedev AV, Tumanov AS, Kim KV, Bobkova MR. [Analysis of Tat protein characteristics in human immunodeficiency virus type 1 sub-subtype A6 (Retroviridae: Orthoretrovirinae: Lentivirus: Human immunodeficiency virus-1)]. Vopr Virusol 2022;66:452-64. [PMID: 35019252 DOI: 10.36233/0507-4088-83] [Reference Citation Analysis]
|
| 6 |
Ensoli B, Moretti S, Borsetti A, Maggiorella MT, Buttò S, Picconi O, Tripiciano A, Sgadari C, Monini P, Cafaro A. New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Arch Virol 2021. [PMID: 34390393 DOI: 10.1007/s00705-021-05158-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Wolkenberg SE, Marrouni AE, Converso A, Tellers DM, Barnard RJO, Diamond TL. Current Status of Approaches to Eradicate HIV Infection. Burger's Medicinal Chemistry and Drug Discovery 2021. [DOI: 10.1002/0471266949.bmc281] [Reference Citation Analysis]
|
| 8 |
Tripiciano A, Picconi O, Moretti S, Sgadari C, Cafaro A, Francavilla V, Arancio A, Paniccia G, Campagna M, Pavone-Cossut MR, Sighinolfi L, Latini A, Mercurio VS, Pietro MD, Castelli F, Saracino A, Mussini C, Perri GD, Galli M, Nozza S, Ensoli F, Monini P, Ensoli B. Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART. EBioMedicine 2021;66:103306. [PMID: 33839064 DOI: 10.1016/j.ebiom.2021.103306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Wang X, Xu H. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Viruses 2021;13:335. [PMID: 33670027 DOI: 10.3390/v13020335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 10 |
Lopes JR, Chiba DE, Dos Santos JL. HIV latency reversal agents: A potential path for functional cure? Eur J Med Chem 2021;213:113213. [PMID: 33540228 DOI: 10.1016/j.ejmech.2021.113213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Cafaro A, Barillari G, Moretti S, Palladino C, Tripiciano A, Falchi M, Picconi O, Pavone Cossut MR, Campagna M, Arancio A, Sgadari C, Andreini C, Banci L, Monini P, Ensoli B. HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. Int J Mol Sci 2020;22:E317. [PMID: 33396807 DOI: 10.3390/ijms22010317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 12 |
Jin H, Li D, Lin MH, Li L, Harrich D. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure. Viruses 2020;12:E415. [PMID: 32276443 DOI: 10.3390/v12040415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 13 |
Thomas J, Ruggiero A, Paxton WA, Pollakis G. Measuring the Success of HIV-1 Cure Strategies. Front Cell Infect Microbiol 2020;10:134. [PMID: 32318356 DOI: 10.3389/fcimb.2020.00134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 14 |
Moretti S, Cafaro A, Tripiciano A, Picconi O, Buttò S, Ensoli F, Sgadari C, Monini P, Ensoli B. HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Rev Vaccines 2020;19:71-84. [PMID: 31957513 DOI: 10.1080/14760584.2020.1712199] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 15 |
Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Buttò S, Monini P, Ensoli B. Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines (Basel) 2019;7:E99. [PMID: 31454973 DOI: 10.3390/vaccines7030099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 16 |
Stoszko M, Ne E, Abner E, Mahmoudi T. A broad drug arsenal to attack a strenuous latent HIV reservoir. Curr Opin Virol 2019;38:37-53. [PMID: 31323521 DOI: 10.1016/j.coviro.2019.06.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
